<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129024</url>
  </required_header>
  <id_info>
    <org_study_id>0914M0622</org_study_id>
    <nct_id>NCT01129024</nct_id>
  </id_info>
  <brief_title>An Open-label Safety Study of S-888711</brief_title>
  <official_title>An Open-label Safety Study of S-888711 in Adult Subjects With Relapsed Persistent or Chronic Immune Thrombocytopenia With or Without Prior Splenectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shionogi Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label, extension study to evaluate the safety of
      S-888711 in the treatment of subjects with immune thrombocytopenia. Patients who participate
      in this study must have completed the Phase 2 double-blind, randomized, placebo controlled
      study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the long-term safety of S-888711</measure>
    <time_frame>From start of treatment Up to three years</time_frame>
    <description>By measuring the number of study participants with AEs as an indication of drug safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess dose requirements for long-term platelet response</measure>
    <time_frame>Up to three years</time_frame>
    <description>Platelet counts will be determined periodically during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess durability of platelet response</measure>
    <time_frame>From start of treatment up to three years</time_frame>
    <description>Platelet counts will be determined periodically during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate bleeding events by World Health Organization (WHO) bleeding criteria</measure>
    <time_frame>From start of treatment up to three years</time_frame>
    <description>Evaluation will utilize World Health Organization (WHO) bleeding criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>S-888711 0.5 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-888711 0.5 mg tablet q.d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-888711 0.5 mg tablet</intervention_name>
    <description>The starting dose was 0.5 mg q.d., if the platelet response was not sufficient, the dose could be increased at 0.5 mg q.d. increments up to 2.0 mg q.d.</description>
    <arm_group_label>S-888711 0.5 mg tablet</arm_group_label>
    <other_name>Lusutrombopag</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed and dated written informed consent

          -  Males and females â‰¥ 18 years of age

          -  All subjects must agree to use barrier contraception

          -  Diagnosis of ITP

          -  Subjects &gt; 60 years must have had a diagnostic bone marrow aspiration

          -  Relapsed persistent or chronic ITP status

          -  Subjects receiving steroid therapy must be on a stable dose

          -  PT and APTT within 20% of the upper limit of normal

          -  Subjects receiving stable dosages of cyclosporine A, mycophenolate mofetil,
             azathioprine, or danazol are allowed

        Exclusion Criteria:

          -  History of clinically important hemorrhagic clotting disorder

          -  Females who are pregnant, lactating, or taking oral contraceptives

          -  History of alcohol/drug abuse or dependence within 1 year

          -  Use of the following drugs or treatment prior to Visit 1 (Day 1):

               -  Within 1 week - Rho(D) immune globulin or intravenous immunoglobulin;

               -  Within 2 weeks - plasmaphoresis treatment;

               -  Within 4 weeks - use of anti-platelet or anti-coagulant drugs;

               -  Within 8 weeks - rituximab;

               -  Within 12 weeks - alemtuzumab, multi-drug systemic chemotherapy, stem cell
                  therapy;

          -  History of clinically significant cardiovascular or thromboembolic disease within 26
             weeks prior to Initial Screening

          -  Splenectomy within 4 weeks prior to Initial Screening

          -  Clinically significant laboratory abnormalities

               -  Hemoglobin &lt; 10.0 g/dL for men or women, not clearly related to ITP

               -  Absolute neutrophil count &lt; 1000/mm3

               -  Abnormal peripheral blood smear with evidence of fibrosis confirmed by bonemarrow
                  biopsy

               -  Total bilirubin &gt; 1.5 x upper limit of normal

               -  Alanine aminotransferase (ALT) &gt; 1.5 x upper limit of normal

               -  Aspartate aminotransferase (AST) &gt; 1.5 x upper limit of normal

               -  Creatinine &gt; 1.5 x upper limit of normal

               -  Human immunodeficiency virus positive

               -  Hepatitis A IgM antibody positive, hepatitis B surface antigen or hepatitis C
                  antibody positive

          -  Exposure to previous TPO mimetics/agonists (e.g., eltrombopag,romiplostim, E5501
             [AKR-501] or LGD-4665) within 4 weeks prior to Initial Screening

          -  Subjects unresponsive to previous TPO mimetics/agonists (e.g., eltrombopag,
             romiplostim, E5501 [AKR-501] or LGD-4665)

          -  Exposure to an investigative medication within 4 weeks prior to the initial Screening
             Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shionogi Clinical Trials Administrator Clinical Support Help Line</last_name>
    <role>Study Director</role>
    <affiliation>Shionogi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90272</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <zip>33426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Riverdale</city>
        <state>Georgia</state>
        <zip>30274</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Jefferson City</city>
        <state>Missouri</state>
        <zip>65109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <disposition_first_submitted>May 18, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>May 18, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 22, 2018</disposition_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Splenectomy</keyword>
  <keyword>Low Platelet Count</keyword>
  <keyword>Thrombopoiesis</keyword>
  <keyword>Thrombocytopaenia</keyword>
  <keyword>Idiopathic Thrombocytopenic Purpura</keyword>
  <keyword>Immune Thrombocytopenia (ITP)</keyword>
  <keyword>Thrombotic Thrombocytopenic Purpura (ITP)</keyword>
  <keyword>Hematologic Disease</keyword>
  <keyword>Auto-immune Thrombocytopenic Purpura</keyword>
  <keyword>S-888711</keyword>
  <keyword>Blood Platelet Disorders</keyword>
  <keyword>Relapsed Persistent or Chronic ITP</keyword>
  <keyword>ITP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

